Cryoport, Inc. Earnings Recaps
Q3 2025
Nov 6, 2025
Cryoport delivered strong third-quarter performance, achieving double-digit growth in both its Life Sciences Services and Products segments, bolstered by significant demand for cell and gene therapy support.
Key takeaways
- Revenue from commercial cell and gene therapy surged 36% year-over-year to $8.3 million, reflecting robust market adaptation.
- Overall Life Sciences revenue rose 16% year-over-year, accounting for 55% of total revenue from continuing operations.
- The launch of next-generation cryogenic systems and new cryopreservation services positions Cryoport for further growth and market leadership.
- A new state-of-the-art global supply chain center opened in Paris enhances service capabilities in European and global markets.
- Strategic partnership with DHL Group poised to bolster market presence in the APAC and EMEA regions over time.